Menu Search
Equities

Pyridam Farma Tbk PT

PYFA:JKT

Pyridam Farma Tbk PT

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (IDR)154.00
  • Today's Change-5.00 / -3.14%
  • Shares traded194.07m
  • 1 Year change-6.24%
  • Beta1.1002
Data delayed at least 10 minutes, as of Sep 18 2024 10:12 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in IDRIncome statement in IDRView more

Year on year Pyridam Farma Tbk PT had net income fall from a gain of 275.24bn to a loss of 85.22bn despite relatively flat revenues. A contributing factor has been an increase in the selling, general and administrative costs as a percentage of sales from 36.72% to 38.75%.
Gross margin38.35%
Net profit margin-19.23%
Operating margin-6.96%
Return on assets-3.99%
Return on equity-16.22%
Return on investment-6.16%
More ▼

Cash flow in IDRView more

In 2023, cash reserves at Pyridam Farma Tbk PT fell by 46.61bn. Cash Flow from Financing totalled 79.84bn or 11.37% of revenues. In addition the company used 103.98bn for operations while cash used for investing totalled 22.46bn.
Cash flow per share-21.50
Price/Cash flow per share--
Book value per share120.12
Tangible book value per share-113.26
More ▼

Balance sheet in IDRView more

Pyridam Farma Tbk PT has a Debt to Total Capital ratio of 74.73%, a lower figure than the previous year's 183.40%.
Current ratio0.7509
Quick ratio0.5474
Total debt/total equity2.96
Total debt/total capital0.7473
More ▼

Growth rates in IDR

Year on year, growth in earnings per share excluding extraordinary items dropped -130.96%.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		-145.58
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.